J Am Soc Nephrol:年龄和肾功能不同的晚期CKD老年患者,透析vs药物对生存期的影响

2018-09-03 王淳 环球医学

2018年8月,发表在《J Am Soc Nephrol》的一项由美国学者进行的分析,在不同年龄和肾功能的晚期CKD老年患者中,考察了透析vs药物管理与生存期之间的相关性

2018年8月,发表在《J Am Soc Nephrol》的一项由美国学者进行的分析,在不同年龄和肾功能的晚期CKD老年患者中,考察了透析vs药物管理与生存期之间的相关性。

背景:晚期CKD老年患者中,合理的患者选择和最佳的初始透析时机未知。研究人员考察了不同年龄和肾功能水平下,透析vs药物管理与生存期之间的相关性。

方法:2005~2010年,研究人员收集了美国全国退伍军人20%的代表性样本(73349人),并随访至2012年,这些退伍军人的eGFR<30ml/min/1.73m2。研究人员使用扩展Cox模型确定时变暴露、年龄(<65,65~74,75~84,≥85岁)、eGFR(<6,6~<9,9~<12,12~<15,15~<29ml/min/1.73m2)、透析和生存期之间的相关性。

结果:平均随访时间3.4±2.2年,在此期间,15%的患者开始透析,52%死亡。与药物管理相比,透析时的eGFR与较低的死亡率相关(P<0.001)。对于<65,65~74,75~84,≥85岁的患者,透析分别与eGFR未超过6~<9、<6、9~<12、9~<12ml/min/1.73m2的患者较低的死亡率相关。eGFR<6ml/min/1.73m2时初始透析分别与65、75和85岁患者中位预期寿命延长26、25和19个月相关。在eGFR为9~<12ml/min/1.73m2时初始透析,这些患者中位预期寿命的估计差异<1年。

结论:在较高的肾功能水平时提供透析会延长一些老年患者的生存期。

原始出处:

Manjula Kurella Tamura, Manisha Desai, Kristopher I. Kapphahn, et.al. Dialysis versus Medical Management at Different Ages and Levels of Kidney Function in Veterans with Advanced CKD. JASN August 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1850686, encodeId=9bdd1850686ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Sep 17 12:47:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378187, encodeId=ec0d13e818756, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 05 09:47:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342523, encodeId=e7f934252390, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Sep 03 23:01:20 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342489, encodeId=b7db3424892e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Sep 03 19:35:08 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-17 yese
  2. [GetPortalCommentsPageByObjectIdResponse(id=1850686, encodeId=9bdd1850686ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Sep 17 12:47:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378187, encodeId=ec0d13e818756, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 05 09:47:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342523, encodeId=e7f934252390, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Sep 03 23:01:20 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342489, encodeId=b7db3424892e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Sep 03 19:35:08 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1850686, encodeId=9bdd1850686ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Sep 17 12:47:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378187, encodeId=ec0d13e818756, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 05 09:47:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342523, encodeId=e7f934252390, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Sep 03 23:01:20 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342489, encodeId=b7db3424892e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Sep 03 19:35:08 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-03 131****2916

    不错的文章值得推荐一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1850686, encodeId=9bdd1850686ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Sep 17 12:47:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378187, encodeId=ec0d13e818756, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 05 09:47:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342523, encodeId=e7f934252390, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Sep 03 23:01:20 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342489, encodeId=b7db3424892e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Sep 03 19:35:08 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-03 orangesking

    0

相关资讯

Curr Eye Res:不同年龄的青光眼晶状体蛋白表达与青光眼损伤的相关性研究

美因茨约翰内斯古腾堡大学医学中心眼科学实验眼科的Anders F近日在Curr Eye Res发表了一篇文章。青光眼是全球失明的主要原因之一,年龄是一个重要的危险因素。然而,对于青光眼的发病机制仍然知之甚少。本研究的目的是关注青光眼实验动物模型中对年龄具有依赖性的分子变化。

ANN ONCOL:直肠癌患者年龄对奥沙利铂有效性的影响

德国直肠癌临床试验CAO/ARO/AIO-04表明在标准的5-FU为基础的放化疗和辅助化疗中加入奥沙利铂可以显着改善局部晚期直肠癌患者的3年无病生存情况。对于年龄较大的结肠癌患者使用奥沙利铂作为辅助治疗一直存在争议。ANN ONCOL近期发表了一篇文章,研究CAO/ARO/AIO-04中年龄对临床结局的影响。

Stroke:优降糖降低年龄<70岁大面积脑梗死患者的死亡率

大面积半球梗死(Large hemispheric infarction,LHI)动脉缺血性卒中的特殊形式,特征为组织明显水肿,常与脑疝、死亡或不良神经功能预后有关。脑水肿会引起颅内压升高,导致其他脑组织损伤,很多情况下会引起脑疝和死亡。

Hepatology:对肝硬化患者的长期随访表明,MELD、年龄和BSA是死亡的主要预测因素

对肝硬化患者的长期随访表明,MELD、年龄和BSA是死亡的主要预测因素;在心血管参数中,左心房增大、心率和E/ E增加、平均血压降低是死亡的独立预测因子。

Semin Arthritis Rheu:迟发性银屑病关节炎:疾病表现、活动性和预后

LoPsA患者起病时的特征是女性占主导、BMI较高、损伤较大、HLA-C*06较少。

Radiology:高龄急性缺血性脑卒中要不要介入治疗呢?

本研究旨在评价老龄缺血性急性脑卒中患者年龄对血管内治疗(EVT)联合常规护理效果的影响,将结果发表在radiology上。